What caused the intraday move in CMB.AX stock today?

The move was a concentrated volume spike in a thinly traded market. Only **8.00** shares printed versus **4,111.00** average volume. Without a new filing, traders likely reacted to block orders or flow ahead of the 26 Feb 2026 earnings date.

What are the main valuation metrics for CMB.AX stock?

Key metrics include EPS **-0.21**, PE **-2.86**, price to sales **20.57**, and price to book **6.03**. These ratios place Cambium Bio above many small-cap biotech peers, reflecting growth expectations and execution risk.

How does Meyka AI view CMB.AX stock right now?

Meyka AI rates CMB.AX with a score out of 100 at **58.79 (C+) — HOLD**. The grade blends benchmark, sector, financial growth, key metrics and analyst signals. This is informational and not investment advice.

What price targets and forecasts exist for CMB.AX stock?

Meyka AI's forecast model projects a monthly figure of **A$0.45** and a quarterly scenario of **A$1.82**. The monthly implies downside **-18.18%**, while the quarterly implies upside **+230.91%** versus the current **A$0.55**. Forecasts are model-based and not guarantees.

AU Stocks

CMB.AX Cambium Bio Ltd (ASX) rises to A$0.55 on volume spike 24 Jan 2026: monitor catalysts

ByHuzaifa Zahoor January 24, 2026January 24, 2026

A sharp intraday volume spike pushed CMB.AX stock to A$0.55 on 24 Jan 2026. We saw only 8.00 shares trade versus a 50-day average of 4,111.00, giving a reported relative volume of 27.81. The move came with no new ASX filing, so traders are watching short-term flows ahead of the company earnings date on 26 Feb 2026. We examine fundamentals, technicals and what a volume spike like this means for active traders and longer-term investors.